<DOC>
	<DOCNO>NCT00384202</DOCNO>
	<brief_summary>Assessment safety efficacy tacrolimus modify release ( MR4 ) base immunosuppressive regimen stable liver transplant subject convert 1:1 ( mg : mg ) basis Prograf® base immunosuppressive regimen .</brief_summary>
	<brief_title>A Conversion Study Assess Safety Efficacy MR4 Based Immunosuppressive Regimen Stable Liver Recipients</brief_title>
	<detailed_description>Multicenter , open , single sequence crossover study . Subject Enrolment : Prograf® administer twice daily replace Prograf study medication , administer twice daily . Six week Prograf-Treatment Phase confirm compliance regimen stability requirement ( see Inclusion Exclusion Criteria ) , collection data Prograf treatment . Conversion Prograf ( twice daily , morning &amp; even dosing ) total daily dose MR4 daily ( morning dosing ) 1:1 ( mg : mg ) basis Day 1 . Twelve week MR4-Treatment Phase study assessment safety efficacy .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>Liver transplant least 12 month prior enrollment . Prograf® dose remain unchanged minimum 12 week prior enrollment tacrolimus whole blood trough level measurement range 515 ng/mL . Any unstable medical condition could interfere study objective opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Liver Transplantation</keyword>
</DOC>